• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

ASTMH 2009

18-22 November 2009

Washington DC, USA

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The Drugs for Neglected Diseases initiative (DNDi) participated in several sessions of the ASTMH 2009 , including a joint symposium with sanofi-aventis on pharmacovigilance of new anti-malarials in the field, a satelllite symposium on ASMQ, the anti-malarial Fixed-Dose Combination of Artesunate-Mefloquine, as well as several oral presentations and posters.

Symposia

Thursday, November 19, 2009 (7:00am—8:00am)

Title: The ASMQ Fixed-Dose Combination to treat Malaria
From Blueprint to Use in the Field
1 year after the launch in Brazil

Chair: Nick White (Mahidol University, Thailand; Oxford University, UK)

Speakers:
puce Jean-René Kiechel (DNDi, Switzerland): “The ASMQ Fixed-Dose Combination”
puce Isabela Ribeiro (DNDi, Switzerland): “Effect of the Artesunate Mefloquine Fixed-Dose Combination in the malaria transmission in Amazon basin communities”
puce Frank Smithuis (Medical Action Myanmar): “Treatment of malaria in Myanmar”

Friday, November 20, 2009 (1:30pm—3:15pm)

Title: Pharmacovigilance of new antimalarials in the field: challenges and
opportunities (joint symposium with sanofi-aventis)

Chair: Wilfred Mbacham (University of Yaoundé, Cameroon)
Co-chair: Rachida Soulaymani (National Pharmacovigilance Center, Rabat, Morocco)

Speakers:
puce Rachida Soulaymani (National Pharmacovigilance Center, Rabat, Morocco): “Pharmacovigilance systems in Africa: North-Africa vs sub-Saharan Africa”
puce Francois Bompart (Sanofi-Aventis, Paris, France): “The artesunate-amodiaquine fixed-dose combination field monitoring program: Objectives, methods, and first results from Liberia and Senegal”
puce Wilfred Mbacham (University of Yaoundé, Cameroon): “Post Licensure Monitoring and Evaluation of Antimalaria Drug Effectiveness and Safety”

Booth

DNDi’s booth is #503. Please visit our team there to find out more information about DNDi’s activities.

Oral Presentations

Thursday, November 19, 2009 (1:30pm—3.15pm)
Session: Malaria – Drug Development
Speaker:
puce Bernhards Ogutu (Kenya Medical Research Institute, Nairobi, Kenya): “Safety, efficacy, tolerability and first population pharmacokinetic study on fixed-dose artesunate/amodiaquine combination versus combined loose drugs for uncomplicated malaria in Kenyan adults”

Saturday, November 21, 2009 (10:15am—12:00pm)
Session: Kinetoplastidia II: Epidemiology, Diagnosis and Treatment
Speakers:
puce Isabela Ribeiro (DNDi) on behalf of Maria Terezinha Bahia (Universidade Federal de Ouro Preto, Brazil): “Combination of Benznidazole and Nifurtimox plus Posaconazole enhances activity against Trypanosoma cruzi in experimental Chagas disease”
puce Michael O. Harhay (University of Pennsylvania, USA): “Calculating drug needs and costs for treating visceral leishmaniasis using local patient anthropometric data from Brazil, East Africa and Indian subcontinent”
puce Stephen Wring (Scynexis, USA): “SCYX-6759, an Orally Bioavailable Oxaborole 6-carboxamide, Achieves Therapeutically Relevant Exposure in Brain and CSF Leading to 100% Cures in a Mouse Model of CNS-stage Human African Trypanosomiasis”
puce Martine Keenan (Epichem, Australia; DNDi Chagas Disease Consortium): “Novel Compounds for the Treatment of Chagas Disease”

Saturday, November 21, 2009 (1:30pm—3:15pm)
Session: Rummaging Through Pharma’s Attic: Taking Advantage of Industry’s Unused Assets to Generate New Products for Infectious Diseases of the Developing World
Speaker:
puce Robert Don (DNDi, Switzerland): “DNDi’s Model and Patent Pools”

Poster Presentations

Thursday, November 19, 2009 (12:00pm—1:30pm)
1. “In Vitro Pharmacodynamics and Mechanism of Action Studies of Oxaborole
6-Carboxamides: A New Class of Compounds for the Treatment of African
Trypanosomiasis”
, by Bakela Nare (Scynexis, USA)

2. “Artemisinin combination therapies: policy and market surveys in
Burundi & Sierra Leone”
, by John Amuasi, DNDi consultant

3. “Efficacy and Pharmacokinetics of SCYX-7158 (AN5568): a Novel and Potent
Oxaborole-6-Carboxamide Selected as a Pre-Clinical Candidate for Once- Daily
Oral Treatment for Stage 2 Human African Trypanosomiasis”
, by Bob Jacobs

Saturday, November 21, 2009 (12:00am—1:30pm)
1. “Lead Optimization of Novel Boron-Containing Drug Candidates for
the Treatment of Human African Trypanosomiasis”
, by Bob Jacobs (Scynexis, USA)

2. “Cost-effectiveness analysis of combination therapies for visceral leishmaniasis
on the Indian subcontinent”, by Filip Meheus (Institute of Tropical Medicine, Antwerp, Belgium)

3. “A new pediatric tablet strength of benznidazole for the treatment of Chagas
disease”
, by Isabela Ribeiro (DNDi, Switzerland)

Other events

Loading...
8-12 May 2023

Lisbon, Portugal and online

ESPID 2023

13 April 2023, 2 PM London

London, United Kingdom

Ending the neglect of Chagas disease in the UK

11-12 April 2023

Barcelona, Spain and online

XVIII Jornadas sobre la enfermedad de Chagas

27-31 March 2023

Online

Global meeting on skin-related neglected tropical diseases

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo